-
Illumina Analysts Question Grail Deal's Commercial Opportunity, Hefty Price Tag
Tuesday, September 22, 2020 - 2:23pm | 520Read More...Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. The Illumina Analysts: Baird analyst Catherine Ramsey Schulte maintained a Neutral rating on Illumina shares and lowered...
-
Deutsche Bank Downgrades Hologic, Says Core Businesses Face Structural Challenges
Friday, January 19, 2018 - 11:05am | 428Read More...Medical diagnostics products maker Hologic, Inc. (NASDAQ: HOLX) is likely to be stifled by secular growth challenges on multiple fronts, Deutsche Bank said in a Thursday note. The Analyst Deutsche Bank analyst Dan Leonard downgraded shares of Hologic from Buy to Neutral with a $46 price...
-
Deutsche Bank Brightens Its View On Illumina
Monday, October 23, 2017 - 1:44pm | 268Read More...Dan Leonard, Deutsche Bank's research analyst, upgraded Illumina, Inc. (NASDAQ: ILMN) from Hold to Buy and increased its 12-month price target from $195 to $250. The analyst is optimistic due to positive newsflow in the clinical markets, which should cause higher enthusiasm about the total...
-
3 Things Deutsche Bank Likes About Agilent's Q3, And One Thing To Be Cautious Of
Wednesday, August 16, 2017 - 11:46am | 507Read More...Agilent Technologies Inc (NYSE: A)'s earnings report was strong enough for Deutsche Bank's Dan Leonard to maintain a Buy rating on the stock with a price target boosted from $66 to $68. Agilent's fiscal third-quarter earnings report highlighted the company's strong end market exposures, product...
-
Waters Shares Up 37% So Far In 2017; Deutsche Bank Downgrades To Hold
Monday, July 10, 2017 - 3:43pm | 397Read More...After a 37 percent gain in 2017, analysts at Deutsche Bank are no longer recommending investors buy shares of Waters Corporation (NYSE: WAT), a developer of analytical laboratory instruments and related software. The firm's Dan Leonard downgraded Waters' stock rating from Buy to Hold but with a...
-
With 'Tunnel's End' In Sight, Deutsche Upgrades Bio-Rad Labs
Wednesday, June 28, 2017 - 12:22pm | 477Read More...Deutsche Bank upgraded shares of Bio-Rad Laboratories, Inc. (NYSE: BIO), as it sees light at the end of the tunnel, given the company's ability to accelerate sales growth and expand margins. Investments To Bear Fruit Analyst Dan Leonard expects the company's outsized investment in...
-
Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector
Wednesday, January 18, 2017 - 1:29pm | 597Read More...Deutsche Bank initiated coverage of 16 companies in the Life Science Tools & Diagnostics sector, with a generally positive view on sector fundamentals, and the bank considers the end market environment more stable than stock volatility suggests. Life Sciences Tools & Diagnostics Sector...
-
Leerink Warns Of Looming Uncertainty In Illumina, Downgrades
Thursday, October 1, 2015 - 9:08am | 314Read More...Illumina, Inc. (NASDAQ: ILMN) shares have plummeted 20 percent in the last three months, after hitting a high of $240.02 on July 20. Leerink’s Dan Leonard downgraded the rating for the company from Outperform to Market Perform, while reducing the price target from $225 to $185....
-
UPDATE: Leerink Swann Downgrades Cellular Dynamics International on Good Story, But Lacking Visibility
Thursday, November 14, 2013 - 10:15am | 145Read More...In a report published Thursday, Leerink Swann analyst Dan Leonard downgraded the rating on Cellular Dynamics International (NASDAQ: ICEL) from Outperform to Market Perform, but reiterated the $15.00 price target. In the report, Leerink Swann noted, “We've reduced our forward revenue estimates for...
